TITLE

Idarubicin intensified BUCY2 regimen in allogeneic unmanipulated transplant for high-risk hematological malignancies

AUTHOR(S)

Mengarelli, A; Iori, A P; Guglielmi, C; Perrone, M P; Gozzer, M; Girmenia, C; Cimino, G; Testi, A M; Ricci, R; De Felice, L; Girelli, G; Mandelli, F; Arcese, W

PUB. DATE

December 2000

SOURCE

Leukemia (08876924);Dec2000, Vol. 14 Issue 12, p2052

SOURCE TYPE

Academic Journal

DOC. TYPE

Article

ABSTRACT

Twenty-nine consecutive patients with high-risk hematological malignancy aged from 3 to 58 years underwent an unmanipul-ated graft from an HLA-identical sibling after an irradiation-free preparative regimen consisting of idarubicin (IDA), 21 mg/m[SUP2]/day administered by continuous infusion on days -12 and -11, followed by busulphan (BU), 4 mg/kg/day orally from day -7 to -4, and cyclophosphamide (CY), 60 mg/kg/day intravenously on days -3 and -2 (IDA-BUCY2). Most clinically relevant extra-hematological regimen-related toxicities consisted of stomatitis observed in all subjects and hemorrhagic cystitis occurred in five cases (17%) within 100 days after transplant. Six patients (21%) developed a grade 2 acute graft-versus-host disease (GVHD) and three (10%) a grade 3 or 4; extensive chronic GVHD was assessed in nine of 22 (41%) evaluable patients. So far, 12 patients have died and 17 are alive, 16 of whom disease-free, 5-41 months after transplant (median, 15 months). The causes of death were related to GVHD in three patients, to sepsis in one and to disease recurrence in the remaining eight. At present, only one of nine relapsed patients is alive. For all patients the actuarial probability of survival (OS) at 1 and 2 years � standard error (s.e.) was 63 � 9% and 52 � 10%, respectively. The actuarial probabilities of disease-free survival (DFS), relapse and transplant-related mortality (TRM) at both 1 and 2 years � s.e. were 53 � 9%, 35 � 9% and 16 � 7%, respectively. These results are encouraging but not substantially different from those obtained in 28 patients with malignancy in advanced phase transplanted after the standard BUCY2 regimen, who had an actuarial probability of OS, DFS, relapse and TRM projected at 10 years � s.e. of 54 � 10%, 57 � 9%, 36 � 9% and 11 � 6%, respectively. Although the retrospective comparison between the two groups does not seem to show any...

ACCESSION #

8882816

Tags: HLA histocompatibility antigens;  LEUKEMIA

 

Related Articles

• HLA class I in acute promyelocytic leukemia (APL): possible correlation with clinical outcome. Bolognesi, E; Cimino, G; Diverio, D; Rapanotti, M C; D�Alfonso, S; Fleischhauer, K; Migliaretti, G; Momigliano-Richiardi, P // Leukemia (08876924);Mar2000, Vol. 14 Issue 3, p393 

  The majority of patients with acute promyelocytic leukemia (APL) possess either a bcr1 or a bcr3 type fusion between PML and RARa genes. The junction sequences may possibly be a target for immune response and influence susceptibility to the disease. In this case, HLA class I allele frequencies...

• HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse. Wetzler, M; Baer, M R; Stewart, S J; Donohue, K; Ford, L; Stewart, C C; Repasky, E A; Ferrone, S // Leukemia (08876924);Jan2001, Vol. 15 Issue 1, p128 

  Human leukocyte antigens (HLA) class I molecules restrict the interaction between cytotoxic T cells and target cells. Abnormalities in HLA class I antigen expression and/or function may provide tumor cells with a mechanism for escaping immune surveillance and resisting T cell-based...

• Is HLA-DR4 or the HLA-DRB1*0402 allele associated with decreased risk for CML? Pawelec, G; Wagner, W // Leukemia (08876924);Jan2001, Vol. 15 Issue 1, p192 

  Discusses whether HLA histocompatibility antigens HLA-DR4 and HLA-DRB1 alleles are associated with the decreased risk of chronic myeloid leukemia (AML). Investigation conducted regarding this association; Role of peptide binding with these alleles in decreasing risks of AML.

• HLA phenotypes in long-term survivors treated with BCG immunotherapy for childhood ALL. Tursz, Thomas; Hors, Jacques; Lipinski, Marc; Aamiel, Jean-Louis // British Medical Journal;5/13/1978, Vol. 1 Issue 6122, p1250 

  In recent years evidence has been produced to show the association of numerous diseases with individual HLA antigens. Theoretically, acute lymphoblastic leukaemia (ALL) was initially supposed to be likely to show such an association, since in mice the susceptibility to virus-induced leukaemia...

• HLA and Hogkin�s disease: reply to Taylor and Gokhale. Dorak, M T; Mills, K I; Poynton, C H; Burnett, A K // Leukemia (08876924);Jun97, Vol. 11 Issue 6, p892 

  Discusses the association between HLA antigens, leukemia and Hodgkin's disease. Consistent association of homozygosity for HLA antigens in hemopoietic malignancies; Role of HLA antigens in the etiology of Hodgkin's disease.

• Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia. Cortes, J; Fayad, L; Kantarjian, H; O�Brien, S; Lee, M-S; Talpaz, M // Leukemia (08876924);Apr98, Vol. 12 Issue 4, p455 

  Twenty to 25% of patients with chronic myelogenous leukemia (CML) treated with interferon-alpha (IFN-A) achieve a complete cytogenetic response (CCR). However, cells bearing rearrangement of BCR/ABL can still be detected many years after achieving a CCR despite the absence of clinical evidence...

• DNA sequencing-based HLA typing detects a B-cell ALL blast-specific mutation in HLA-A*2402 resulting in loss of HLA allele expression. Sayer, D.C.; Smith, L.K.; Krueger, R.; Chrisitansen, F.T. // Leukemia (08876924);Jan2004, Vol. 18 Issue 1, p174 

  Presents a letter to the editor of "Leukemia" journal about an article describing the DNA sequence of HLA histocompatibility antigen typing of mutations in B cell acute lymphoblastic leukemia.

• HLA-DR antigen-negative acute myeloid leukemia. Wetzler, M; McElwain, B K; Stewart, C C; Blumenson, L; Mortazavi, A; Ford, L A; Slack, J L; Barcos, M; Ferrone, S; Baer, M R // Leukemia (08876924);Apr2003, Vol. 17 Issue 4, p707 

  Human leukocyte antigen (HLA) Class II antigens are variably expressed on acute myeloid leukemia (AML) blasts. The biological and clinical significance of HLA Class II antigen expression by AML cells is not known. Therefore, we sought to characterize cases of AML without detectable HLA-DR...

• Identification of natural killer cell receptor phenotypes associated with leukemia. Verheyden, S.; Bernier, M.; Demanet, C. // Leukemia (08876924);Dec2004, Vol. 18 Issue 12, p2002 

  Natural killer (NK) cells play a key role in defense against tumor cells that have the capacity to downregulate human leukocyte antigen (HLA) class I expression. It has been reported that leukemic cells can have downregulated expression of HLA class I molecules. The polymorphic nature of NK cell...

Read the Article